Back to all news
New Report Highlights Clinical AI Performance, Sustainability, and Adoption Challenges
A multi-institutional review details key challenges, progress, and sustainability concerns in deploying clinical AI in real-world healthcare settings.
Key Details
- 1ARISE network (Stanford, Harvard, Virginia, Minnesota) reviewed high-impact 2025 clinical AI studies.
- 2Real-world impact lags behind model capabilities, with few studies demonstrating measurable outcomes.
- 3Frontier LLMs excel in reasoning but struggle with uncertainty or context change.
- 4Clinicians value workflow automation, but key target use cases are understudied.
- 5FDA clearance for AI is increasing, but narrow, domain-specific tools are most likely to gain adoption.
- 6Sustainability concerns rise; AI models and data centers contribute significant carbon emissions.
Why It Matters
This review provides evidence-based guidance for translating AI advances from research to practice, underscoring the importance of rigorous standards, transparency, and sustainability. Imaging AI professionals should note the trend toward regulatory approvals and practical clinical impact, as well as institutional responsibility for environmental considerations.
Source
HealthExec
Related News
•Radiology Business
AI Analyzes Mammograms to Assess Post-Surgery Breast Cancer Recurrence Risk
A new AI tool predicts likelihood of breast cancer recurrence after surgery using pre-operative mammograms.
•Radiology Business
AI Model Aims to Detect Placenta Accreta Earlier in Pregnancy
Researchers present a new AI model to help diagnose placenta accreta spectrum before delivery.
•Radiology Business
FDA Clears Median's Eyonis AI for CT Lung Cancer Screening
Median Technologies' Eyonis LCS, an AI tool for low-dose CT lung cancer screening, receives FDA clearance.